Status:
RECRUITING
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
Lead Sponsor:
Takeda
Conditions:
Cytomegalovirus (CMV)
Eligibility:
All Genders
19+ years
Brief Summary
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. LIVTENCITY (Maribavir) is ...
Eligibility Criteria
Inclusion
- Participants with post-transplant CMV infection and/or disease who are refractory and/or resistant to one or more prior therapy including ganciclovir, valganciclovir, cidofovir or foscarnet.
- Participants with age greater than or equal to (\>=) 19 years.
- Initiate first treatment course with maribavir.
- Voluntarily consent to participate in the study.
Exclusion
- Participants for whom LIVTENCITY Tablet (maribavir) is contraindicated as per product label.
- Participants previously treated with maribavir in any study or as marketed drug.
- Participants actively participating in other clinical trials of post-transplant CMV infection treatment or with other experimental treatments.
Key Trial Info
Start Date :
November 14 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT06555432
Start Date
November 14 2024
End Date
October 1 2028
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea, 06591